Back to Search

MARTIN MARKOWITZ, MD

MD

Infectious Disease Physician

NPI: 1790987030Individual

Specialties, Licenses & Credentials

Infectious Disease PhysicianPrimary

Internal Medicine — Infectious Disease

Code: 207RI0200X

145826(NY)

Clinical Trials (1)

1
Linked Trials
0
Recruiting
1
With Results

Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs

NCT02347345COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR

Research & Publications (20)

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
PMID 24720702·N Engl J Med·2014
3-trial
Telbivudine improves renal function in patients with chronic hepatitis B.
PMID 24067879·Gastroenterology·2014
3-trial
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
PMID 24209977·Lancet·2014
3-trial
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.
PMID 19648823·J Acquir Immune Defic Syndr·2009
2-rct
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
PMID 17721395·J Acquir Immune Defic Syndr·2007
4-observational
Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study.
PMID 17554217·J Acquir Immune Defic Syndr·2007
3-trial
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
PMID 17133211·J Acquir Immune Defic Syndr·2006
4-observational
Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
PMID 15980684·J Acquir Immune Defic Syndr·2005
3-trial
A randomized trial of calcium supplementation for childhood lead poisoning.
PMID 14702492·Pediatrics·2004
3-trial
A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo.
PMID 12663814·J Virol·2003
8-other

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
455 1ST AVE, 7TH FLOOR AARON DIAMOND AIDS RESEARCH CENTER
NEW YORK, NY 10016

Quick Facts

NPI
1790987030
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
1
Locations
1
Clinical Trials
1
Publications
20

Are you this provider?

Claim Your Profile